1,721,068 research outputs found

    4. Nuovi materiali per la produzione di canali di dentina artificiale per la valutazione della strumentazione endodontica e l’esercitazione clinica endodontica

    No full text
    Bibliographic data: ITNA20020060 (A1) ― 2004-04-12 MATERIALI PER LA PRODUZIONE DI CANALI DI DENTINA ARTIFICIALE PER LA VALUTAZIONE DELLA STRUMENTAZIONE ENDODONTICA E L'ESERCITAZIONE CLINICA ENDODONTICA. Page bookmark ITNA20020060 (A1) - MATERIALI PER LA PRODUZIONE DI CANALI DI DENTINA ARTIFICIALE PER LA VALUTAZIONE DELLA STRUMENTAZIONE ENDODONTICA E L'ESERCITAZIONE CLINICA ENDODONTICA. Inventor(s): APICELLA ANTONIO; DE ROSA ALFREDO; GAMBARINI GIANLUCA; SCHIRALDI CHIARA + (APICELLA ANTONIO, ; DE ROSA ALFREDO, ; GAMBARINI GIANLUCA, ; SCHIRALDI CHIARA) Applicant(s): APICELLA ANTONIO; DE ROSA ALFREDO; GAMBARINI GIANLUCA; SCHIRALDI CHIARA + (APICELLA ANTONIO, ; DE ROSA ALFREDO, ; GAMBARINI GIANLUCA, ; SCHIRALDI CHIARA) Classification: - international: A61K6/00; (IPC1-7): A61K6/00 - Euro: Application number: IT2002NA00060 20021011 Priority number(s): IT2002NA00060 20021011 Abstract not available for ITNA20020060 (A1

    Composti inibitori dello sviluppo del virus HIV, loro preparazione e usi

    No full text
    Sono descritti composti ciclici di formula generale: f-Al-A27A3-Al-ASin (I) in cui: Al e A2 rappresentano qualsiasi imminoadido e posseno essere uguali o di-versi tra loro, A3 e A4 rappresentano qualsiasi amminoacido idrofobico e possono essere uguali o diversi tra loro; A5 rappresenta un braccio tpaziatore di lunghezza compresa tra circa 12 e 21 A, legato covalentemente alle estremità N-terminale di Al e C-terminale di A4. I composti sono attivi come inibitori dello sviluppo dei virus HIV

    THROMBIN INHIBITORS, THE PREPARATION THEREOF AND THE USE THEREOF FOR THERAPEUTICAL, PROPHYLACTIC AND DIAGNOSTIC APPLICATIONS

    No full text
    Peptides having 25 to 27 amino acids capable of binding both to the catalytic site and to the non-catalytic site of hirudin

    Desmoglein 3 in apoptotic keratinocytes: participation of MAPK pathway, caspase 3, and metalloproteinase 9

    No full text
    Desmoglein 3 (Dsg3) is known to undergo proteolysis by caspases and matrix metalloproteinases (MMPs) during apoptosis, that associates with profound changes in ce11 shape and loss of intercellular contacts. Here we show that cells undergoing apoptosis may weaken their cohesion strength by acting on multiple molecular levels, such as transcriptional and translational regulation of molecules involved in cell adhesion, including Dsg3. First, we have demonstrated that induction of apoptosis in keratinocytes by staurosporine (STS) proceeds through the activation of the Raf-MEK-ERK pathway (death signal) as well as p38 MAPK phosphorylation. These changes were followed by reduction in the amount of surface Dsg3, as revealed by immunofluorescence microscopy, and paralleled with depletion of fulllength Dsg3 and its fragmentation by Western blotting. At the same time, Dsgl, Dsg2, and Ecadherin mRNA levels underwent slight down-regulation, as shown by RT-PCR analysis. Then, by using an in vitro essay, we were able to demonstrate the direct cleavage of Dsg3 by caspase 3. Furthermore, Western blot analysis and zymography revealed an increased matrix metalloproteinase (MMP)-9 protein expression and activity, respectively. Immunofluorescence studies confirmed the sustained secretion of MMP-9 within intercellular spaces upon induction of apoptosis. These changes paralleled with dramatic reduction of ce11 adhesion strength among keratinocytes, that was partially prevented in the presence of MMP inhibitors. However, we were unable to demonstrate the direct cleavage of Dsg3 by MMP-9. Overall, these data demonstrate that keratinocytes undergoing STS-induced apoptosis (a) activate MAPK pathway; (b) modulate transcription of cadherin genes; (C) process Dsg3 by caspase 3-activity (d) weaken intercellular cohesion strength through the action of MMPs, including MMP-9. Key ulouds: desmoglein 3, apoptosis, MAPK, MMP-9, caspase

    PROCESS FOR THE PREPARATION OF IODINATED BIOPOLYMERS HAVING DISINFECTANT AND CICATRIZING ACTIVITY, AND THE IODINATED BIOPOLYMERS OBTAINABLE THEREBY

    No full text
    Process for the preparation of complexes of iodine with chitosan or derivatives thereof, and the iodinated com-pounds thus obtainable. Said compounds take form of pow¬ders, which may contain over 60% of iodine in its elemen¬tary form. In a dry state the iodine bound to the chitosan or derivatives thereof does not sublimate. If the percentage content of iodine does not exceed 50 % (by weight), said powders can be dissolved in aqueous solvents of an acid type, such as, for example, diluted acetic acid or glutamic acid. Said solutions are compatible with addition of surfac¬tants, preferably of a non-ionic type, which improve the solubility of the chitosan-iodine complex. Solutions with identical characteristics can, altematively, be prepared by solubilizing, heating if necessary the iodine in a suitable surfactant, preferably non-ionic, and adding this solution under rapid stirring to the chitosan derivatives thereof, dissolved in water, optionally in the presence of acids or salts. Altematively, the chitosan or derivatives thereof in a dry state can be added to the solution of iodine in surfactant which rapidly absorbs onto the solid, forming the chitosan¬iodine complexes. This material suspended in water or in acid solutions, preferably acetic acid or glutamic acid, solubilizes rapidly. The complexes of iodine with chitosan or derivatives thereof, in the form of aspersable powders, solutions or ointments, thanks to their disinfectant and cicatrizing properties, can be used in the field of surgery post-operative treatment and more generally speaking as products for topical use for medication of wounds and disinfectation of the skin. Another area of interest in which the complexes can be used as an attive principle is the field of cosmetics

    PROCESS FOR OBTAINING HYALURONIC ACID OF DEFINED MOLECULAR WEIGHT

    No full text
    PROCESS FOR OBTAINING HYALURONIC ACID OF DEFINED MOLECULAR WEIGHT ABSTRACT A process is described for obtaining, in an innovative, simple and economical manner, hyaluronic acid and hyaluronans at varying molecular weight.

    Development of a new calcium sulphate-based composite using alginate and chemically modified chitosan for bone regeneration

    No full text
    In this work we developed a novel calcium sulphate- based composite in which the hemihydrate calcium sulphate (CHS) can be encapsulated in a polymeric biodegradable and biocompatible matrix, in order to retain the structural integrity and decrease the bioresorption rate in bone regeneration applications. Two polymers were employed to realize this system: chitosan (Ch) and sodium alginate (Alg), both already widely used in biotechnological and biomedical applications. Chitosan was modified in order to obtain a water soluble polymer, the N-succinylchitosan (sCh). The reaction was performed with succinic anhydride in presence of pyridine and confirmed by FT-IR and NMR analyses. Finely ground Alg and sCh powders were mixed in different compositions with CHS and by adding water to the powder mixture it was obtained a mouldable paste that sets in few hours. Thermogravimetric analyses coupled with solvent extraction performed on the composite proved the alginate crosslinking in the presence of CHS. Mechanical studies carried out on composites of different compositions demonstrated that the blend of the two polymeric components causes a substantial synergistic reinforcement of composites. The presence of carboxylic groups on sCh chain in addition to those of alginate could enhance the chelating power of polysaccharide mixture. The results obtained with morphological analyses (SEM) further confirmed the hypotesis of the synergistic effect between alginate and N-succinylchitosan in presence of calcium sulphate. In vitro cytotoxicity tests proved that the developed system was not cytotoxic. 2007 Wiley Periodicals, Inc. J Biomed Mater Res 81A: 811–820, 200
    corecore